Core Viewpoint - The SHS Innovation Drug Index has shown significant growth, reflecting the performance of listed companies involved in innovative drug research and production in both mainland China and Hong Kong [1]. Group 1: Index Performance - The SHS Innovation Drug Index increased by 4.03%, reaching 2393.56 points, with a trading volume of 54.435 billion [1]. - Over the past month, the index has risen by 11.98%, and over the last three months, it has increased by 35.45%. Year-to-date, the index has surged by 47.88% [1]. Group 2: Index Composition and Adjustments - The index is composed of up to 50 representative securities selected from mainland and Hong Kong markets, focusing on companies engaged in innovative drug development and production [1]. - The index is adjusted semi-annually, with changes implemented on the next trading day following the second Friday of June and December each year. Weight factors are generally fixed until the next adjustment [1]. - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or splits [1].

Group 1 - The core viewpoint of the article highlights the performance of the CSI Hong Kong-Shanghai Innovative Drug Industry Index, which rose by 2.51% to 1955.39 points, with a trading volume of 33.441 billion yuan [1] - The index has shown significant growth, increasing by 6.55% over the past month, 12.29% over the past three months, and 22.60% year-to-date [1] - The index is composed of up to 50 representative securities from the mainland and Hong Kong markets, focusing on companies involved in innovative drug research and production, reflecting the overall performance of the innovative drug industry [1] Group 2 - The index is adjusted semi-annually, with changes implemented on the next trading day following the second Friday of June and December each year [1] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [1] - The index will be modified if a sample company is delisted or if there are significant corporate changes such as mergers or acquisitions [1] Group 3 - Public funds tracking the SHS Innovative Drug Index include various ETFs and fund products from companies like Guotai, Xizang Dongcai, and Huatai Bairui [2]